{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:46:46Z","timestamp":1788436006674,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A variety of osteolytic factors have been identified from breast cancer cells leading to osteolysis, but less is known about which factor plays an essential role in the initiation process prior to the overt vicious osteolytic cycle. Here, we present in vitro and in vivo evidences to clarify the role of interleukin-11 (IL-11) as an essential contributor to breast cancer bone metastasis mediated osteolysis. Animal studies showed that bone specific metastatic BoM-1833 cells induce earlier onset of osteolysis and faster tumor growth compared with MCF7 and parental MDA-MB-231 cells in BALB\/c-nu\/nu nude mice. IL-11 was further screened and identified as the indispensable factor secreted by BoM-1833 cells inducing osteoclastogenesis independently of receptor activator of nuclear factor \u03baB ligand (RANKL). Mechanistic investigation revealed that the JAK1\/STAT3 signaling pathway as a downstream effector of IL-11, STAT3 activation further induces the expression of c-Myc, a necessary factor required for osteoclastogenesis. By inhibiting STAT3 phosphorylation, AG-490 was shown effective in reducing osteolysis and tumor growth in the metastatic niche. Overall, our results revealed the essential role and the underlying molecular mechanism of IL-11 in breast cancer bone metastasis mediated osteolysis. STAT3 targeting through AG-490 is a potential therapeutic strategy for mitigating osteolysis and tumor growth of bone metastatic breast cancer.<\/jats:p>","DOI":"10.1038\/s41419-019-1594-1","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T09:03:43Z","timestamp":1556615023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis"],"prefix":"10.1038","volume":"10","author":[{"given":"Mengmeng","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6983-6354","authenticated-orcid":false,"given":"Ce","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,30]]},"reference":[{"key":"1594_CR1","first-page":"7","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA 68, 7\u201330 (2018).","journal-title":"CA"},{"key":"1594_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy, G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584\u2013593 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"1594_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ccr.2009.05.017","volume":"16","author":"XH Zhang","year":"2009","unstructured":"Zhang, X. H. et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16, 67\u201378 (2009).","journal-title":"Cancer Cell"},{"key":"1594_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/ncb0511-513","volume":"13","author":"E Fuchs","year":"2011","unstructured":"Fuchs, E. & Horsley, V. Ferreting out stem cells from their niches. Nat. Cell Biol. 13, 513\u2013518 (2011).","journal-title":"Nat. Cell Biol."},{"key":"1594_CR5","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/nm.1943","volume":"15","author":"M Korpal","year":"2009","unstructured":"Korpal, M. et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15, 960\u2013966 (2009).","journal-title":"Nat. Med."},{"key":"1594_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","volume":"11","author":"KN Weilbaecher","year":"2011","unstructured":"Weilbaecher, K. N., Guise, T. A. & McCauley, L. K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11, 411\u2013425 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"1594_CR7","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","volume":"95","author":"H Yasuda","year":"1998","unstructured":"Yasuda, H. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc. Natl Acad. Sci. USA 95, 3597\u20133602 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1594_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165\u2013176 (1998).","journal-title":"Cell"},{"key":"1594_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature14492","volume":"522","author":"TR Cox","year":"2015","unstructured":"Cox, T. R. et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522, 106\u2013110 (2015).","journal-title":"Nature"},{"key":"1594_CR10","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1002\/art.39837","volume":"68","author":"W O\u2019Brien","year":"2016","unstructured":"O\u2019Brien, W. et al. RANK-independent osteoclast formation and bone erosion in inflammatory arthritis.Arthritis Rheumatol. 68, 2889\u20132900 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1594_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12016-015-8523-6","volume":"51","author":"A Sabokbar","year":"2016","unstructured":"Sabokbar, A., Mahoney, D. J., Hemingway, F. & Athanasou, N. A. Non-Canonical (RANKL-Independent) pathways of osteoclast differentiation and their role in musculoskeletal diseases. Clin. Rev. Allergy Immunol. 51, 16\u201326 (2016).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"1594_CR12","first-page":"5571","volume":"62","author":"MS Bendre","year":"2002","unstructured":"Bendre, M. S. et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. 62, 5571\u20135579 (2002).","journal-title":"Cancer Res."},{"key":"1594_CR13","first-page":"5911","volume":"61","author":"G Dong","year":"2001","unstructured":"Dong, G. et al. Hepatocyte growth factor\/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 61, 5911\u20135918 (2001).","journal-title":"Cancer Res."},{"key":"1594_CR14","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/sj.bjc.6602417","volume":"92","author":"SE Aldridge","year":"2005","unstructured":"Aldridge, S. E., Lennard, T. W., Williams, J. R. & Birch, M. A. Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone. Br. J. Cancer 92, 1531\u20131537 (2005).","journal-title":"Br. J. Cancer"},{"key":"1594_CR15","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1359\/jbmr.060416","volume":"21","author":"T Shimo","year":"2006","unstructured":"Shimo, T. et al. Pathogenic role of connective tissue growth factor (CTGF\/CCN2) in osteolytic metastasis of breast cancer. J. Bone Mineral Res. 21, 1045\u20131059 (2006).","journal-title":"J. Bone Mineral Res."},{"key":"1594_CR16","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/sj.bjc.6600858","volume":"88","author":"T Ohshiba","year":"2003","unstructured":"Ohshiba, T., Miyaura, C., Inada, M. & Ito, A. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br. J. Cancer 88, 1318\u20131326 (2003).","journal-title":"Br. J. Cancer"},{"key":"1594_CR17","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.4049\/jimmunol.151.5.2555","volume":"151","author":"T Yin","year":"1993","unstructured":"Yin, T. et al. Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. J. Immunol. 151, 2555\u20132561 (1993).","journal-title":"J. Immunol."},{"key":"1594_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0304-3835(01)00524-9","volume":"169","author":"C Sotiriou","year":"2001","unstructured":"Sotiriou, C. et al. Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. Cancer Lett. 169, 87\u201395 (2001).","journal-title":"Cancer Lett."},{"key":"1594_CR19","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1084\/jem.182.5.1461","volume":"182","author":"N Udagawa","year":"1995","unstructured":"Udagawa, N. et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J. Exp. Med. 182, 1461\u20131468 (1995).","journal-title":"J. Exp. Med."},{"key":"1594_CR20","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1172\/JCI117130","volume":"93","author":"G Girasole","year":"1994","unstructured":"Girasole, G., Passeri, G., Jilka, R. L. & Manolagas, S. C. Interleukin-11: a new cytokine critical for osteoclast development. J. Clin. Investig. 93, 1516\u20131524 (1994).","journal-title":"J. Clin. Investig."},{"key":"1594_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","volume":"3","author":"Y Kang","year":"2003","unstructured":"Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537\u2013549 (2003).","journal-title":"Cancer Cell"},{"key":"1594_CR22","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1073\/pnas.042372199","volume":"99","author":"O Solakoglu","year":"2002","unstructured":"Solakoglu, O. et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc. Natl Acad. Sci. USA 99, 2246\u20132251 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1594_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.str.2007.02.006","volume":"15","author":"R Matadeen","year":"2007","unstructured":"Matadeen, R., Hon, W. C., Heath, J. K., Jones, E. Y. & Fuller, S. The dynamics of signal triggering in a gp130-receptor complex. Structure 15, 441\u2013448 (2007).","journal-title":"Structure"},{"key":"1594_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.cytogfr.2015.07.015","volume":"26","author":"CN Johnstone","year":"2015","unstructured":"Johnstone, C. N., Chand, A., Putoczki, T. L. & Ernst, M. Emerging roles for IL-11 signaling in cancer development and progression: focus on breast cancer. Cytokine Growth Factor Rev. 26, 489\u2013498 (2015).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1594_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/379645a0","volume":"379","author":"N Meydan","year":"1996","unstructured":"Meydan, N. et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379, 645\u2013648 (1996).","journal-title":"Nature"},{"key":"1594_CR26","doi-asserted-by":"publisher","first-page":"7319","DOI":"10.1073\/pnas.131568898","volume":"98","author":"T Bowman","year":"2001","unstructured":"Bowman, T. et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl Acad. Sci. USA 98, 7319\u20137324 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1594_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1359\/jbmr.2002.17.5.763","volume":"17","author":"R Battaglino","year":"2002","unstructured":"Battaglino, R. et al. c-myc is required for osteoclast differentiation. J. Bone Mineral Res. 17, 763\u2013773 (2002).","journal-title":"J. Bone Mineral Res."},{"key":"1594_CR28","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1172\/JCI89935","volume":"127","author":"S Bae","year":"2017","unstructured":"Bae, S. et al. MYC-dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERRalpha. J. Clin. Investig. 127, 2555\u20132568 (2017).","journal-title":"J. Clin. Investig."},{"key":"1594_CR29","doi-asserted-by":"publisher","first-page":"11001","DOI":"10.1158\/0008-5472.CAN-05-2630","volume":"65","author":"MS Bendre","year":"2005","unstructured":"Bendre, M. S. et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res. 65, 11001\u201311009 (2005).","journal-title":"Cancer Res"},{"key":"1594_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-16","volume":"13","author":"EM McCoy","year":"2013","unstructured":"McCoy, E. M., Hong, H., Pruitt, H. C. & Feng, X. IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells. BMC Cancer 13, 16 (2013).","journal-title":"BMC Cancer"},{"key":"1594_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6798","volume":"5","author":"H Zhang","year":"2014","unstructured":"Zhang, H. et al. STAT3 restrains RANK- and TLR4-mediated signalling by suppressing expression of the E2 ubiquitin-conjugating enzyme Ubc13. Nat. Commun. 5, 5798 (2014).","journal-title":"Nat. Commun."},{"key":"1594_CR32","first-page":"174.177","volume":"188","author":"H Zhang","year":"2012","unstructured":"Zhang, H. et al. Crosstalk between STAT3 and RANK signaling pathways during osteoclastogenesis (174.7). J. Immunol. 188, 174.177\u2013174.177 (2012).","journal-title":"J. Immunol."},{"key":"1594_CR33","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1182\/blood.V100.7.2530","volume":"100","author":"KJ Walton","year":"2002","unstructured":"Walton, K. J., Duncan, J. M., Deschamps, P. & Shaughnessy, S. G. Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. Blood 100, 2530\u20132536 (2002).","journal-title":"Blood"},{"key":"1594_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.189.1.63","volume":"189","author":"N Kiuchi","year":"1999","unstructured":"Kiuchi, N. et al. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J. Exp. Med. 189, 63\u201373 (1999).","journal-title":"J. Exp. Med."},{"key":"1594_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0634-4","volume":"30","author":"L Ren","year":"2013","unstructured":"Ren, L., Wang, X., Dong, Z., Liu, J. & Zhang, S. Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130\/STAT3 pathway. Med. Oncol. 30, 634 (2013).","journal-title":"Med. Oncol."},{"key":"1594_CR36","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1158\/1078-0432.CCR-06-2765","volume":"13","author":"C Desmedt","year":"2007","unstructured":"Desmedt, C. et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 13, 3207\u20133214 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1594_CR37","doi-asserted-by":"publisher","first-page":"13909","DOI":"10.1073\/pnas.0506517102","volume":"102","author":"Y Kang","year":"2005","unstructured":"Kang, Y. et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl Acad. Sci. USA 102, 13909\u201313914 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1594_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","volume":"15","author":"S Grivennikov","year":"2009","unstructured":"Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103\u2013113 (2009).","journal-title":"Cancer Cell"},{"key":"1594_CR39","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/ijc.29923","volume":"138","author":"K Banerjee","year":"2016","unstructured":"Banerjee, K. & Resat, H. Constitutive activation of STAT3 in breast cancer cells: A review. Int. J. Cancer 138, 2570\u20132578 (2016).","journal-title":"Int. J. Cancer"},{"key":"1594_CR40","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/0008-5472.CAN-09-2468","volume":"70","author":"L Lin","year":"2010","unstructured":"Lin, L. et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 70, 2445\u20132454 (2010).","journal-title":"Cancer Res."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1594-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1594-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1594-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:40:46Z","timestamp":1694828446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1594-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5]]}},"alternative-id":["1594"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-1594-1","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,30]]},"assertion":[{"value":"1 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"353"}}